clinical trial · NCT07081256
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
Qilu Pharmaceutical Co., Ltd.·phase3·completed·n = 665
Chemotherapy-Induced Nausea and VomitingQLM2010 for injection；dexamethasonefosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
brief summary
Compared With Fosaprepitant dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of QLM2010 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
started
Jan 3, 2025
primary completion
Aug 25, 2025
completion
Oct 15, 2025
last updated
Nov 18, 2025
official title
A Multicenter, Randomized, Double-blind, Double-dummy, Positive-controlled Phase III Trial, to Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol